QHSLab Inc. (OTCMKTS:USAQ) Enters into Strategic Alliance with Medical License Factory, Primarily for its AllergiEnd Products and Services
QHSLab, Inc. (OTCMKTS:USAQ) offers digital healthcare solutions and point-of-care-diagnostic tests to primary care physicians. Digital healthcare lets doctors understand patients’ responses faster and more effectively, via sophisticated artificial intelligence. It can also remotely monitor patients’ vital signs and determine effects of prescribed medicines and treatments on patients’ health through real-time data transferred from patient to doctor.
Market Stats
On Friday, USAQ stock ended flat at $0.34 with more than 5 shares, compared to its average volume of 2K share. The stock moved within a range of $0.3400 – 0.3400 after opening trading at $0.34.
QHSLab Announces New Strategic Alliance with Medical License Factory For its AllergiEnd® Products and Services
QHSLab, Inc. has announced a strategic alliance with Medical License Factory, LLC, which is a renowned physician licensing and management services organization, for its AllergiEnd allergy diagnostic and allergen immunotherapy products and clinical decision support digital health services.
Medical License Factory will enable working relationships between QHSLab and Medical License Factory’s network of physicians, while providing administrative, medical billing, recruitment services, marketing, and promotional support for the new partnership.
Troy Grogan, CEO of QHSLab, says that this announcement proves they have made tremendous progress while expanding the the independent medical provider practice network. The steadily growing adoption of AllergiEnd’s allergy diagnostic services and allergen immunotherapy products is evidence of their patient-centered tools and income-producing services for medical practices.
He further elaborates that the services being provided proactively addresses chronic diseases, offers preventive care, and enables the broad market of general practitioner physicians to expand their practices and reimbursement base, especially in times of rising interest rates, inflation, and labor expenses.
Lilia Waldero, President of Medical License Factory, is equally thrilled to be collaborating with QHSLab, which is set to improve the working relationship with their network of independent medical practices while helping to introduce their services to current QHSLab physicians. The AllergiEnd allergy diagnostic and allergen immunotherapy products are highly needed additions to the primary care practice that benefit physician clients and their patients, while including a new income stream to the practice.
QHSLab and Medical License Factory share common goals and complementary methods of supporting physicians with services required to boost clinical outcomes, streamline practice operations, increase practice revenue, and provide cost-effective solutions. Medical License Factory has over a decade of experience in various critical practice-management modalities, including medical licensing, recruiting, quality assurance, medical billing, human resources, and healthcare marketing support.
Key Quote
“Today’s announcement is further evidence of our continued progress and momentum as we expand our independent medical provider practice network. The growing adoption of AllergiEnd®’s allergy diagnostic services and allergen immunotherapy products reflects the attractiveness of our patient-centered tools and income-producing services for medical practices. Our services proactively address chronic diseases, provide preventive care, and enable the broad market of general practitioner physicians to expand their practices and reimbursement base, especially in times of rising interest rates, inflation, and labor costs,” said Troy Grogan, CEO of QHSLab.
Traders Corner
USAQ stock is trading below the 20-Day and 50-Day Moving averages of $0.4587 and $0.5037 respectively. Moreover, the stock is trading below the 200-Day moving average of $0.6525.